Testing for a BRAF V600 mutation and the oral drug combinations that target it
Bring a printable list of questions to your appointment, or share this page with someone who needs it.
Roughly 40 to 50 percent of melanomas that start in the skin carry a specific change in a gene called BRAF. The change — almost always in a spot known as V600, and most often the version called V600E (V600K is the next most common) — leaves a growth switch inside the melanoma cells stuck in the "on" position. Targeted therapy is a set of pills designed to flip that switch back off.
Two drugs are always used together: a BRAF inhibitor and a MEK inhibitor. The BRAF inhibitor blocks the faulty BRAF protein directly; the MEK inhibitor blocks the next relay in the same chain. Together they control the melanoma more deeply and for longer than a BRAF inhibitor alone, with fewer skin side effects.
This article explains how a BRAF mutation is found, which drug pairs are approved, how well they work, and — importantly — why most people with BRAF-mutant melanoma are still advised to start with immunotherapy rather than targeted therapy. For the bigger picture of how melanoma is treated at every stage, see melanoma treatment options.
BRAF is a gene that helps make a protein in the MAPK pathway — a molecular chain that tells a cell when to grow and divide. A V600 mutation changes one building block of that protein so it signals constantly, without waiting for the normal "go" message. The result is uncontrolled growth, and in a large share of melanomas this is the main engine of the cancer.
Melanomas that arise on the palms, soles, or nail beds (acral) or on mucous membranes carry BRAF V600 mutations less often than sun-related skin melanomas do, and uveal (eye) melanoma essentially never does.
Early on, BRAF inhibitors were tried on their own. They worked, but melanoma cells found a way around the block within months by reactivating the same pathway one step further down, at a protein called MEK. Adding a MEK inhibitor closes that escape route.
Three BRAF-plus-MEK pairs are approved for BRAF V600-mutant advanced melanoma. All are taken by mouth at home, with regular clinic visits for blood tests, skin checks, heart scans, and eye checks. They have never been compared directly against one another, and their benefits are broadly similar; the choice comes down to the side-effect profile, other medical conditions, and physician experience.
The most widely used pair and the one with the longest follow-up. Its distinctive side effect is a fever-and-chills reaction (see below). It is also the combination approved to be given after surgery for certain stage III melanomas.
Often the best tolerated of the three, with less fever and less sun sensitivity for many people. In the COLUMBUS trial it produced a median overall survival of roughly 33 months.
The oldest pair. Marked sun sensitivity is common, so strict sun protection is essential. It is used less often now that the other two are available.
Targeted therapy often works fast. Many people feel better within days to a couple of weeks, tumors shrink on the first scan, and a high lactate dehydrogenase (LDH) level frequently falls. That speed makes it valuable when melanoma is causing symptoms — pain, breathing trouble, pressure on an organ — or when there is a large amount of disease that needs to be brought under control quickly.
The limitation is durability. In most people the melanoma eventually adapts and finds a new way to send the growth signal, and the disease starts to grow again — usually within about one to two years. A minority do considerably better: in long-term follow-up of dabrafenib plus trametinib, roughly one third of patients were alive at five years, and a smaller group remained free of progression.
Because response tends to be quick but time-limited, targeted therapy is often thought of as a way to gain control — either as a bridge, or held in reserve — rather than the treatment most likely to produce a lasting remission.
If a melanoma is BRAF-mutant, both immunotherapy and targeted therapy are available — which raises the question of what to use first. The randomized DREAMseq trial (also called ECOG-ACRIN EA6134) was designed to answer it. Patients received either the nivolumab-plus-ipilimumab immunotherapy combination first, or dabrafenib plus trametinib first, and switched to the other approach if the melanoma progressed.
This is a general guide, not a rule for every case. The right order depends on how fast the disease is moving, the tumor burden and LDH, other health conditions, and your own priorities — a conversation for a melanoma specialist team.
Targeted therapy is not chemotherapy, and its side effects differ from those of immunotherapy. Most are manageable with dose adjustments, short breaks, and supportive medicines, and many settle once the body adjusts. Common and important ones include:
Targeted therapy is not only for melanoma that cannot be removed. For melanoma that has spread to lymph nodes and been completely taken out with surgery (resected stage III) and is BRAF V600E or V600K positive, one year of dabrafenib plus trametinib given afterward lowers the chance the melanoma comes back. In the COMBI-AD trial this adjuvant course roughly halved the risk of relapse in the first few years, and the benefit has held up with long follow-up.
For resected stage III BRAF-mutant melanoma, then, there is a choice between adjuvant targeted therapy and adjuvant immunotherapy. Both reduce recurrence; they differ in their side effects and in how they are given. This decision is covered in adjuvant therapy after surgery.
BRAF and MEK targeted therapy gives people whose melanoma carries a BRAF V600 mutation a fast, effective way to shrink the cancer and relieve symptoms. Used as a pair, the drugs control the disease more deeply and for longer than a single BRAF inhibitor, with fewer skin side effects. For most people, though, the melanoma eventually learns to grow around the block within one to two years.
That is why, for most BRAF-mutant advanced melanoma, the current advice is to start with immunotherapy and keep targeted therapy in reserve — for disease that is moving too fast to wait, for situations where immunotherapy is unsafe, and for use after immunotherapy. After surgery for BRAF-mutant stage III disease, targeted therapy is one of two good options for lowering the risk of recurrence. A melanoma specialist team can help you weigh the order that fits your case.
Disclaimer: This article is for educational purposes only and not a substitute for professional medical advice. Always consult a qualified dermatologist or oncologist about your personal diagnosis and treatment plan.
Chat with our AI guide for information about advanced melanoma
Chat with the Navigator